Inventor · disambiguated record
Gregory Babcock
Also filed as: BABCOCK GREGORY · BABCOCK GREGORY J
33 granted patents·23 pending applications·170 citations·filing 2004–2025
97Inventor score
Files withVISTERRA INC38UNIV MASSACHUSETTS11AMBROSINO DONNA M4AMBROSINO DONNA1CT FOR DISEASE CONTROL AND PREVENTION1
Top patents by PatentIndex Score
56 records- 0197US11136385B2Methods of treating IgA nephropathy by administering an anti-APRIL (a proliferation-inducing ligand) antibody moleculeVISTERRA INC·Filed 2020·Granted Oct 5, 2021·4 cites·38 claims
- 0297US10954296B2Method of using anti-APRIL (a proliferation-inducing ligand) antibodies to reduce IGAVISTERRA INC·Filed 2020·Granted Mar 23, 2021·4 cites·51 claims
- 0397US9212217B2Antibody molecules to dengue virus and uses thereofVISTERRA INC·Filed 2015·Granted Dec 15, 2015·14 cites·21 claims
- 0496US10968270B2Antibody molecules to a proliferation-inducing ligand (APRIL)VISTERRA INC·Filed 2020·Granted Apr 6, 2021·3 cites·30 claims
- 0596US9365639B2Antibody molecules to dengue virus and uses thereofVISTERRA INC·Filed 2015·Granted Jun 14, 2016·9 cites·30 claims
- 0696US7625559B2Antibodies against Clostridium difficile toxins and uses thereofUNIV MASSACHUSETTS·Filed 2005·Granted Dec 1, 2009·47 cites·4 claims
- 0794US8257709B2Antibodies against Clostridium difficile toxins and uses thereofAMBROSINO DONNA M·Filed 2009·Granted Sep 4, 2012·22 cites·23 claims
- 0893US10385123B2Antibody molecules to a proliferation-inducing ligand (APRIL)VISTERRA INC·Filed 2018·Granted Aug 20, 2019·8 cites·30 claims
- 0992US10155806B2Antibody molecules to dengue virus and uses thereofVISTERRA INC·Filed 2016·Granted Dec 18, 2018·4 cites·30 claims
- 1092US8236311B2Antibodies against clostridium difficile toxins and uses thereofAMBROSINO DONNA M·Filed 2009·Granted Aug 7, 2012·15 cites·25 claims
- 1191US2025066464A1Nucleic acid molecules encoding antibodies to a proliferation-inducing ligand (april)VISTERRA INC·Filed 2024·Application pending·0 cites
- 1289US11912781B2Humanized complement 5A receptor 1 antibodies and methods of use thereofVISTERRA INC·Filed 2022·Granted Feb 27, 2024·1 cites·10 claims
- 1389US2024425569A1Antibody molecules to dengue virus and uses thereofVISTERRA INC·Filed 2024·Application pending·0 cites
- 1488US11059883B2Antibody molecules to dengue virus and uses thereofVISTERRA INC·Filed 2018·Granted Jul 13, 2021·2 cites·30 claims
- 1587US10981982B2Nucleic acid molecules encoding antibodies to a proliferation-inducing ligand (APRIL)VISTERRA INC·Filed 2020·Granted Apr 20, 2021·1 cites·48 claims
- 1686US12297249B2Interleukin-2 agents and uses thereofVISTERRA INC·Filed 2024·Granted May 13, 2025·0 cites·13 claims
- 1786US12264203B2Humanized complement 5a receptor 1 antibodies and methods of use thereofVISTERRA INC·Filed 2024·Granted Apr 1, 2025·0 cites·13 claims
- 1885US9109037B2Anti-SOD1 antibodies and uses thereofAMBROSINO DONNA·Filed 2011·Granted Aug 18, 2015·7 cites·25 claims
- 1985US8226952B2Human antibodies against rabies and uses thereofTHOMAS JR WILLIAM D·Filed 2010·Granted Jul 24, 2012·9 cites·23 claims
- 2085US7727532B2Human antibodies against rabies and uses thereofUNIV MASSACHUSETTS·Filed 2007·Granted Jun 1, 2010·6 cites·26 claims
- 2184US12227587B2Humanized complement 5A receptor 1 antibodies and methods of use thereofVISTERRA INC·Filed 2024·Granted Feb 18, 2025·0 cites·10 claims
- 2283US12415865B2Antibody molecules to C5AR1 and uses thereofVISTERRA INC·Filed 2023·Granted Sep 16, 2025·0 cites·2 claims
- 2383US12187807B2Antibody molecules to C5AR1 and uses thereofVISTERRA INC·Filed 2023·Granted Jan 7, 2025·0 cites·4 claims
- 2483US8609111B2Antibodies against clostridium difficile toxins and uses thereofAMBROSINO DONNA M·Filed 2012·Granted Dec 17, 2013·4 cites·30 claims
- 2581US2025059249A1Interleukin-2 agents and uses thereofVISTERRA INC·Filed 2024·Application pending·0 cites
- 2680US12091451B2Method of using antibody molecules to detect a proliferation-inducing ligand (APRIL)VISTERRA INC·Filed 2021·Granted Sep 17, 2024·0 cites·18 claims
- 2780US9217029B2Antibodies against clostridium difficile toxins and uses thereofUNIV MASSACHUSETTS·Filed 2013·Granted Dec 22, 2015·2 cites·25 claims
- 2878US12054539B2Antibody molecules to dengue virus and uses thereofVISTERRA INC·Filed 2021·Granted Aug 6, 2024·0 cites·20 claims
- 2975US7396914B2SARS nucleic acids, proteins, antibodies, and uses thereofUNIV MASSACHUSETTS·Filed 2004·Granted Jul 8, 2008·6 cites·12 claims
- 3075US2021269511A1Antibodies against clostridium difficile toxins and uses thereofUNIV MASSACHUSETTS·Filed 2020·Application pending·0 cites
- 3174US2025043014A1Antibody molecules to april and uses thereofVISTERRA INC·Filed 2024·Application pending·0 cites
- 3274US2024141334A1Binding polypeptides and methods of making the sameVISTERRA INC·Filed 2023·Application pending·0 cites
- 3372US8551484B2Human antibodies against hepatitis C virus (HCV) and uses thereofAMBROSINO DONNA M·Filed 2008·Granted Oct 8, 2013·1 cites·18 claims
- 3471US12084484B2Interleukin-2 agents and uses thereofVISTERRA INC·Filed 2020·Granted Sep 10, 2024·0 cites·23 claims
- 3571US11773179B2Antibody molecules to C5aR1 and uses thereofVISTERRA INC·Filed 2021·Granted Oct 3, 2023·0 cites·4 claims
- 3671US9663586B2Anti-SOD1 antibodies and uses thereofUNIV MASSACHUSETTS·Filed 2015·Granted May 30, 2017·1 cites·25 claims
- 3771US2025171555A1Humanized complement 5a receptor 1 antibodies and methods of use thereofVISTERRA INC·Filed 2025·Application pending·0 cites
- 3870US2024092921A1Antibody molecules to april and uses thereofVISTERRA INC·Filed 2023·Application pending·0 cites
- 3970US2019330326A1Antibody molecules to a proliferation-inducing ligand (april)VISTERRA INC·Filed 2019·Application pending·0 cites
- 4070US2024376173A1Methods of using interleukin-2 agentsVISTERRA INC·Filed 2024·Application pending·0 cites
- 4166US12098178B2Methods of using interleukin-2 agentsVISTERRA INC·Filed 2021·Granted Sep 24, 2024·0 cites·31 claims
- 4266US2023416372A1IMMUNOSILENCING Fc VARIANTSVISTERRA INC·Filed 2023·Application pending·0 cites
- 4366US2018208643A1Antibodies against clostridium difficile toxins and uses thereofUNIV MASSACHUSETTS·Filed 2018·Application pending·0 cites
- 4463US2017145086A1Antibody molecules to april and uses thereofVISTERRA INC·Filed 2016·Application pending·0 cites
- 4562US2015315266A1Human antibodies against rabies and uses thereofUNIV MASSACHUSETTS·Filed 2014·Application pending·0 cites
- 4661US2024041981A1Methods of using interleukin-2 agentsVISTERRA INC·Filed 2022·Application pending·0 cites
- 4760US2022226442A1Interleukin-2 agents and uses thereofVISTERRA INC·Filed 2022·Application pending·0 cites
- 4859US2016152694A1Antibodies against clostridium difficile toxins and uses thereofUNIV MASSACHUSETTS·Filed 2015·Application pending·0 cites
- 4956US11820979B2Binding polypeptides and methods of making the sameVISTERRA INC·Filed 2017·Granted Nov 21, 2023·0 cites·32 claims
- 5056US2013039926A1Human antibodies against rabies and uses thereofCT FOR DISEASE CONTROL AND PREVENTION·Filed 2012·Application pending·0 cites
Showing the top 50 of 56 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Gregory Babcock files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →